PsyScan e-tool to support diagnosis and management of psychological problems in general practice: a randomised controlled trial

Abstract

Background

GPs are crucial in adequately diagnosing and initiating appropriate management for patients with psychological problems, but face many challenges and require support.

Aim

To determine the effects of the e-tool PsyScan.

Design and setting

A randomised controlled trial with a 1-year follow-up, comparing care using PsyScan with usual care for psychological problems, was undertaken in 10 multidisciplinary primary healthcare centres in Eindhoven, the Netherlands.

Method

Between consultations with their GP, participants in the intervention group could complete PsyScan. The e-tool consists of a distress screener and Four-Dimensional Symptom Questionnaire to differentiate between stress, depression, anxiety, and somatisation symptoms, and to explore symptom severity. PsyScan generated diagnostic and therapeutic advice for GPs and participants that was automatically transferred to each patient’s electronic medical record. The primary outcome was the proportion of participants who achieved a successful treatment result; namely, a decrease of ≥50% on the Symptom Checklist-R-90 Revised, after 1 year.

Results

There were 176 participants in the intervention group and 160 in the control group. After multiple imputation, the participants in the intervention group had higher chances of achieving a successful treatment result compared with those in the control group (odds ratio [OR] 2.7, 95% confidence interval [CI] = 1.5 to 4.8, P = 0.002). Quality of life was higher in the intervention group at 12 months (mean difference in EuroQol 5 Dimensions 5 Levels index values was 0.076, 95% CI = 0.015 to 0.136, P = 0.01). The mean 1-year costs per participant were similar €13,622 in intervention group, €12,487 in control group (P = 0.03, P = 0.71, R² = 0.025).

Conclusion

PsyScan generated clinically relevant and statistically significant effects, and could be useful in offering effective individualised care to patients.

Keywords

general practice; mental health; patient portals; psychosocial support systems; randomised controlled trial.

INTRODUCTION

Globally, psychological problems are among the major threats to people’s health, healthcare systems, and the controllability of healthcare costs.1-3 Most patients with psychological problems first present in general practice,4,5 so it is crucial to correctly diagnose them and initiate appropriate management in that setting.

Numerous issues in general practice regarding patients with psychological problems have been described, including under- and overdiagnosis, no assessment of symptom severity, no use of standardised instruments, diagnostic and therapeutic uncertainty, and management inadequacy.4-13 As such, there is a need for tools that can support GPs with the diagnosis and management of patients who present with psychological problems.

Several internet-based tools already exist and have been described and evaluated, these showed increased effectiveness and efficacy for achieving reliable diagnostic results, positive effects on recognition and diagnosis, higher response and remission rates, less polypharmacy, fewer medication side effects, greater satisfaction with treatment, and higher quality of life (QOL).14-27 However, the authors felt that some essential components were missing in the available tools, including:

- being based on the perceived needs of healthcare providers and patients;
- coverage of the broad range of psychological problems, instead of focusing on one specific problem;
- pragmatism in daily practice;
- translation of diagnostic information into therapeutic options; and
- facilitation of data registration in routinely used electronic medical records (EMRs).14-27

As a result, together with a multidisciplinary team of health professionals and patients, the authors developed PsyScan. Its clinical effects were evaluated, based on the hypothesis that its use would lead to more appropriate management of patients and better health in general practice.

METHOD

Design

PsyScan is a stepped tailor-made e-tool that patients can use to get therapeutic advice between consultations with their GP; it can aid doctors by providing them with diagnostic advice. A randomised controlled trial (RCT) with a parallel 1:1 group allocation and 1-year follow-up was undertaken between December 2013 and October 2015 to compare care using PsyScan with usual care for psychological problems.

Participants

PsyScan was developed and evaluated by the researchers in the Eindhoven Corporation of Primary Health Care Centres, the Netherlands.

Luc G Gidding, MD, PhD candidate in family practice; M Spigt, PhD, associate professor of family practice; B Winkens, PhD, associate professor of statistics and methodology; G-J Dinant, MD, professor of family practice, Care and Public Health Research Institute, Maastricht University, the Netherlands; O Herijgers, MD, GP, the Eindhoven Corporation of Primary Health Care Centres, the Netherlands.

Address for correspondence
Luc Gidding, P. Debyeplein 1, 6229 HA Maastricht, the Netherlands.

E-mail: luc.gidding@maastrichtuniversity.nl
©British Journal of General Practice
This is the full-length article (published online 19 Dec 2017) of an abridged version published in print. Cite this version as: Br J Gen Pract 2017; DOI: https://doi.org/10.3399/bjgp17X694109
Corporation of Primary Health Care Centres (Stichting Gezondheidscentra Eindhoven [SGE]), which included 10 multidisciplinary care centres with 44 GPs, offering primary care to approximately 70,000 registered patients; this constituted about one-third of the population of Eindhoven, which is the fifth largest city in the Netherlands. In the Netherlands, GPs are gatekeepers in primary care; patients can only consult a specialist after referral from a GP.

People who were registered with SGE were eligible if they consulted their GP and met the following inclusion criteria:

- had (suspected) psychological problems;
- were aged ≥ 18 years;
- were able to consent;
- had adequate understanding of the Dutch language;
- were able to receive e-mail and use PsyScan at home.

Patients were excluded if they:

- had clear and treatable somatic causes of symptoms;
- had acute distress or danger (either physically or mentally that warranted immediate action from the GP); or
- gave no written informed consent.

Randomisation

Randomisation using the sequentially numbered, opaque, sealed-envelope method took place during the initial consultation, before participants gave informed consent, so the study did not cause any delay in patient care.28 Block randomisation (block size 16) was applied. All GPs received a folder with eight envelopes leading to intervention and eight to the control condition, randomly sequenced.

After the GPs explained the study, checked eligibility criteria, and the eligible patient consented to participate, an envelope was opened, which contained study information, a brief consent form, a detailed consent form, and a registration form. Patients were asked to sign the brief consent form immediately and to return the detailed consent form after 3 days; this ensured they had ample time to think seriously about participating in the study. The brief consent form and registration form were immediately faxed to the researchers, after which they registered the intervention group participants in PsyScan. Control group participants continued to receive usual care after opening the envelope. Patients who did not return the detailed consent form were not followed up and were excluded from the study.

Crossover of control participants was not possible because they were not able to log onto PsyScan. Due to the nature of the intervention, participants and care providers were not blinded for group allocation.

PsyScan intervention

Information on the development of PsyScan is available from the authors on request. Intervention group participants immediately received a follow-up appointment for 1 week later. On the same day, they received an e-mail to log on to PsyScan. Once logged on, they filled in the three-question distress screener.29 If their score was positive (>3), participants were asked to complete the Four-Dimensional Symptom Questionnaire (4DSQ), a 50-item questionnaire designed to differentiate between stress, depression, anxiety, and somatisation, and to explore severity.30,31 If their score was not positive they received on-screen information that at this moment PsyScan did not indicate any psychological problems but that it was still advisable to have the follow-up appointment in 1 week with the GP to further discuss the matter. The 4DSQ was validated in primary care and is recommended for use in the guidelines of Dutch GPs.32–34

The authors developed an algorithm to translate the possible scores on the 4DSQ into:

- diagnostic advice, given as possible International Classification of Primary Care (ICPC) codes; and
- therapeutic advice, given as possible treatment or referral options.
Participants received on-screen, individualised information about symptoms and possible treatments, based on Dutch guidelines. Additionally, a cause inventory was administered, consisting of questions that participants could answer in their own words. These addressed areas that could be the cause of symptoms, such as family and friends, work, finances, housing, physical symptoms, memory, mourning, eating and drinking, addictions, impulse control and anger, sexuality, loneliness, mobility, social media stress, or other. Here, participants could also indicate goals related to possible treatment(s); another person, such as a partner or relative, could also give additional information.

The 4DSQ results, the cause inventory, and diagnostic and therapeutic advice were automatically transferred to the participant’s dossier in the EMR held by the GP. During the scheduled follow-up appointment, the participant and GP discussed the results and initiated management. The participants were asked not to initiate any therapies before the follow-up appointment with the GP because the choice was wanted for therapy to be a shared decision between GP and patient.

Outcomes

Main study parameter and endpoint. The proportion of participants that achieved a decrease of ≥50% on the Symptom Checklist-90-Revised (SCL-90-R) was measured after 1 year. SCL-90-R scores can range from 90 to 450; higher scores indicate higher symptom levels.

Secondary study parameters and endpoints. The following were evaluated:

- SCL-90-R scores after 3, 6, and 12 months;
- QOL after 3, 6, and 12 months. This was assessed using the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. EQ-5D-5L visual analogue scale (VAS) scores can range from 0 to 100; higher scores indicate higher QOL. Answers to the five EQ-5D-5L questions were converted to index values. Dutch EQ-5D-5L index values can range from -0.329 to 1.000; higher values indicate higher QOL;
- participant satisfaction with the care they received. This was scored after 3, 6, and 12 months using the Patient Assessment of Chronic Illness Care (PACIC). The PACIC consists of 20 items and the overall summary score can range from 1 to 5, with higher scores indicating higher levels of satisfaction;
- PsyScan results and percentages of participants that received an ICPC code and were treated/referred in accordance with the PsyScan advice;
- relevant care parameters. These were registered by GPs during follow-up and extracted from the EMR to monitor: changes in referrals to psychology and psychiatry; the use of minimal interventions, including brief counselling, bibliotherapy, mindfulness, psychoeducation, problem-solving therapy, or referral to a social worker; physical exercise therapies, including running therapy, physiotherapy, manual therapy, and Cesar therapy; and pharmaceutical therapy with anxiolytics, hypnotics and sedatives, antidepressants, and psychiatric medication overall (all Anatomical Therapeutic Chemical classification ‘N’ groups combined).
healthcare consumption in primary and secondary care, use of prescribed and over-the-counter medication, absenteeism, and productivity loss to perform a cost-effectiveness analysis. The Trimbos/iMTA questionnaire for Costs Associated with Psychiatric Illness (TiC-P) was completed after 3, 6, 9, and 12 months, and EMR parameters referred to in Table 1. An incremental cost-effectiveness ratio (ICER) was calculated based on the primary outcome and mean total costs.

**Sample size**
A successful treatment result was defined as a decrease of ≥50% in SCL-90-R score after 1 year. It was assumed that a successful result would occur in 70% of participants receiving usual care and a difference of 10% was considered to be clinically relevant by the study team. Assuming a significance level of \( \alpha = 0.05 \) and power of 0.80, at least 289 participants were required based on the \( \chi^2 \) test. Taking a 10% dropout rate into account, according to Rigby and Vail's statistical methods, it was calculated that 322 participants had to be included per group.

**Statistical methods**
A logistic regression analysis was performed to evaluate the primary outcome. As well as the complete case analysis, where only participants with no missing values were included, multiple imputation for chained equations was also performed, using fully conditional specification to account for missing values. In this way, 40 complete datasets were created; group (intervention/ control), age, sex, socioeconomic status, prior psychological problems, and baseline SCL-90-R scores were used as predictors. To assess longitudinal effects, linear mixed models with time, group, and group*time as fixed factors were used for numerical secondary outcomes that were measured repeatedly. This analysis method accounts for baseline differences and dependence between repeated measures within the same participant, where an unstructured covariance structure was used for the repeated measures. A likelihood-based approach was used for missing outcome values in these linear mixed models. Categorical secondary outcomes, with only one measurement during follow-up, were analysed with logistic regression analyses, whereas continuous secondary outcomes were measured with linear regression analyses.

Socioeconomic status based on postal codes was derived from status scores from the Netherlands Institute for Social Research; higher scores indicate higher socioeconomic status. Prior psychological symptoms were defined as the patient having an episode of any chapter 'P' (psychological) ICPC code between July 2003 and the study inclusion date recorded in their EMR.

Sensitivity analyses were performed to assess the influence of clustering of participants in centres and of individual GPs, using generalised estimating equations for categorical outcomes and linear mixed models for numerical outcomes. Statistical procedures were performed by two researchers using IBM SPSS (version 21.0), during which they were blinded for group allocation. The level of statistical significance was set at \( P \leq 0.05 \).

**RESULTS**
GPs randomised 535 patients from December 2013 through to September 2014.
Of these, 199 were excluded either because they did not return the detailed consent form or because of other exclusion criteria. Of the remaining 336, 176 participants were included in the intervention group and 160 in the control group (Figure 1). Twenty-five of those in the intervention group did not use PsyScan, either due to technical difficulties or severe psychological problems. In total, 289 (86%) of the participants returned the baseline SCL-90-R, 158 (47%) returned it at 3 months, 128 (38%) at 6 months, and 205 (61%) at 12 months. Participants’ baseline characteristics are shown in Table 2.

### Outcomes

The results of all regression and mixed-model analyses — adjusted for age, sex, socioeconomic status, prior psychological symptoms, and baseline SCL-90-R score — are presented here; crude analyses are available from the authors on request.

#### Main study parameter and endpoint

In total, 196 participants were included in the logistic regression complete case analysis for the primary outcome (102 participants from the intervention group and 94 from the control group). Of the 102 intervention participants, 61 (60%) achieved a successful treatment result, compared with 30 (32%) in the control group (odds ratio [OR] 3.1, 95% confidence interval [CI] = 1.7 to 5.7, \( P < 0.001 \)). To account for missing values, multiple imputation was performed; this produced an OR of 2.7 (95% CI = 1.5 to 4.8, \( P = 0.002 \)).

Sensitivity analyses, which were performed to test the influence of centres and individual GPs, showed similar results for both the adjusted and crude analyses.

#### Secondary study parameters and endpoints

All 336 participants were included in the adjusted linear mixed model analyses (Figure 2), which resulted in a statistically significant difference in the mean decrease of the SCL-90-R score after 12 months between the groups (mean difference –18.3, 95% CI = –32.0 to –4.7, \( P = 0.009 \), Table 3). EQ-5D VAS scores showed the largest difference after 6 months (mean difference 6.3, 95% CI = 1.2 to 11.4, \( P = 0.01 \)), whereas mean index values showed the greatest difference after 12 months (mean difference 0.076, 95% CI = 0.015 to 0.136, \( P = 0.01 \)) (Table 3). No statistically significant differences were observed in the PACIC scores (Table 3). Sensitivity analyses showed similar results for adjusted and crude analyses.

#### PsyScan and healthcare parameters

In total, 151 intervention participants completed PsyScan. Of these, 22 had a negative distress screener score. In the intervention group, GPs’ actions and PsyScan advice were in accordance with each other in terms of ICPC coding in 45% (\( n = 68 \)) of cases, medication in 93% (\( n = 141 \)) of cases, and treatment/referral in 97% (\( n = 147 \)) of cases (Table 4).

Referral rates to psychology or psychiatry were 17% (\( n = 30 \)) and 12% (\( n = 21 \)) in the intervention group, and 10% (\( n = 16 \)) and 6% (\( n = 9 \)) in the control group respectively (Table 1). Psychiatric medication was prescribed to <42% of participants. In the

### Table 2. Participants’ baseline characteristics (\( n = 336 \))

<table>
<thead>
<tr>
<th></th>
<th>Intervention group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total, n</td>
<td>176</td>
<td>160</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>123 (70)</td>
<td>109 (68)</td>
</tr>
<tr>
<td>Mean age at inclusion, years (SD)</td>
<td>42.4 (13.8)</td>
<td>42.9 (14.1)</td>
</tr>
<tr>
<td>Mean socioeconomic status score (SD)</td>
<td>0.174 (1.012)</td>
<td>–0.137 (1.003)</td>
</tr>
<tr>
<td>With prior psychological symptoms or disorders, n (%)</td>
<td>123 (70)</td>
<td>108 (68)</td>
</tr>
<tr>
<td>Mean baseline SCL-90-R score (SD)</td>
<td>178.7 (54.1)</td>
<td>173.5 (57.1)</td>
</tr>
<tr>
<td>Mean baseline EQ-5D-5L VAS score (SD)</td>
<td>61.6 (19.0)</td>
<td>65.0 (16.9)</td>
</tr>
<tr>
<td>Mean baseline EQ-5D-5L index (SD)</td>
<td>0.699 (0.191)</td>
<td>0.716 (0.191)</td>
</tr>
</tbody>
</table>

EQ-5D-5L = EuroQol 5 Dimensions 5 Levels. SCL-90-R = Symptom Checklist-90-Revised. SD = standard deviation. VAS = visual analogue scale.
intervention group, all non-pharmaceutical therapies were deployed more often and all pharmaceutical therapies less often than in the control group (Table 1).

Cost-effectiveness analysis. All in all, 174 participants completed the TiC-P and SCL-90-R, and were included in the cost-effectiveness analysis based on the primary outcome. The mean 1-year cost per participant in the intervention group was €13,622 (standard deviation [SD] €16,398) and €12,487 (SD €14,862) per control. A linear regression analysis showed no statistically significant influence of group allocation on the mean 1-year costs ($\beta = –0.03$, $P = 0.71$, $R^2 = 0.05$, Table 5).

Of these 174 participants, 58% ($n = 55$) of the intervention group and 38% ($n = 30$) of the control group achieved a successful treatment result ($\text{OR} = 2.2$, 95% CI = 1.1 to 4.1, $P = 0.02$, data not shown). This resulted in an ICER of 57.0, indicating that, for every 1% of patients that achieved a successful treatment result based on care with PsyScan, the cost was €57.00 more per year than the cost of usual care.

DISCUSSION
Summary
PsyScan generated clinically relevant and statistically significant effects: intervention participants had statistically significantly higher chances of achieving symptom reduction of ≥50% after 1 year and reported better QOL scores. Care based on PsyScan was associated with comparable costs in the control group. GPs generally acted according to the advice generated by the e-tool.

Strengths and limitations
A bottom-up approach, involving patients and all relevant disciplines, was used to develop PsyScan. This was crucial and made it easier to motivate GPs to both use the e-tool and participate in the research. This strength was illustrated by the high accordance of GPs’ actions with the PsyScan treatment advice. Accuracy with the PsyScan’s registration/ICPC advice was lower (45%) but this might be explained by the timing in relation to the initial consultation because Dutch GPs are used to registering their actions episode-oriented (that is, attributing actions to an ICPC code episode). Therefore, whenever patients consulted their GP, the GP ascribed an ICPC code to the consultation, before the PsyScan results arrived, as opposed to starting treatment or referral, which was done after obtaining the results.

Another strength is that PsyScan differentiates between problems rather than focusing on one distinct psychological issue. It also provides both diagnostic

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intervention group, mean (SE)</th>
<th>Control group, mean (SE)</th>
<th>Corrected mean difference</th>
<th>95% CI</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCL-90-R, mean total score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>179 (4.1)</td>
<td>171 (4.2)</td>
<td>7.8</td>
<td>–3.2 to 18.8</td>
<td>0.17</td>
</tr>
<tr>
<td>3 months</td>
<td>165 (5.1)</td>
<td>158 (5.4)</td>
<td>–0.8</td>
<td>–11.0 to 9.5</td>
<td>0.88</td>
</tr>
<tr>
<td>6 months</td>
<td>157 (5.3)</td>
<td>154 (5.5)</td>
<td>–4.3</td>
<td>–15.5 to 6.9</td>
<td>0.45</td>
</tr>
<tr>
<td>12 months</td>
<td>135 (4.7)</td>
<td>146 (4.8)</td>
<td>–18.3</td>
<td>–32.0 to –4.7</td>
<td>0.009</td>
</tr>
<tr>
<td><strong>EQ-5D-5L, mean VAS score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>61.5 (1.1)</td>
<td>66.0 (1.2)</td>
<td>–4.5</td>
<td>–7.6 to –1.5</td>
<td>0.004</td>
</tr>
<tr>
<td>3 months</td>
<td>68.6 (1.5)</td>
<td>69.6 (1.7)</td>
<td>3.5</td>
<td>–1.0 to 8.1</td>
<td>0.13</td>
</tr>
<tr>
<td>6 months</td>
<td>71.5 (1.7)</td>
<td>69.7 (1.8)</td>
<td>6.3</td>
<td>1.2 to 11.4</td>
<td>0.01</td>
</tr>
<tr>
<td>12 months</td>
<td>71.6 (2.1)</td>
<td>70.3 (2.3)</td>
<td>5.8</td>
<td>–0.3 to 11.9</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EQ-5D-5L, mean index</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.706 (0.011)</td>
<td>0.737 (0.011)</td>
<td>–0.031</td>
<td>–0.061 to 0.001</td>
<td>0.04</td>
</tr>
<tr>
<td>3 months</td>
<td>0.749 (0.018)</td>
<td>0.760 (0.020)</td>
<td>0.020</td>
<td>–0.032 to 0.071</td>
<td>0.45</td>
</tr>
<tr>
<td>6 months</td>
<td>0.778 (0.018)</td>
<td>0.775 (0.019)</td>
<td>0.035</td>
<td>–0.017 to 0.066</td>
<td>0.19</td>
</tr>
<tr>
<td>12 months</td>
<td>0.807 (0.020)</td>
<td>0.763 (0.022)</td>
<td>0.076</td>
<td>0.015 to 0.136</td>
<td>0.01</td>
</tr>
<tr>
<td>PACIC, mean score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 months</td>
<td>2.9 (0.0)</td>
<td>2.9 (0.0)</td>
<td>0.1</td>
<td>–0.0 to 0.2</td>
<td>0.14</td>
</tr>
<tr>
<td>6 months</td>
<td>2.8 (0.1)</td>
<td>2.9 (0.1)</td>
<td>–0.1</td>
<td>–0.4 to 0.2</td>
<td>0.38</td>
</tr>
<tr>
<td>12 months</td>
<td>2.8 (0.1)</td>
<td>3.0 (0.1)</td>
<td>–0.3</td>
<td>–0.5 to 0.0</td>
<td>0.08</td>
</tr>
</tbody>
</table>

$^a$The adjusted mean differences after 3, 6, and 12 months were adjusted for the corresponding difference in mean baseline score. EQ-5D-5L = EuroQol 5 Dimensions 5 Levels. PACIC = Patient Assessment of Chronic Illness Care. SCL-90-R = Symptom Checklist-90-Revised. SE = standard error; VAS = visual analogue scale.
information and therapeutic options, and was linked to EMRs.

Use of an e-tool, as opposed to a paper questionnaire, offers important advantages as it allows for relevant information to be exchanged between patients and healthcare providers without taking up extra time.51,52 In the case of PsyScan, additional benefits, including automatically generated scores and advice, and no duplication of data by healthcare providers, were incorporated.

Unlike freely available e-tools (which have no standard terms of use that are monitored within the practice), PsyScan was integrated into general practice and supervised by GPs; this ensured that patients received proper advice on how to use it and appropriate follow-up.

The end of the study period was decided on for pragmatic and financial reasons. A major limitation was the loss to follow-up; this was high, despite efforts from the study team to prevent dropout. Although participating in scientific studies can be difficult for any patient, it is possible that participants in this study found it particularly hard, due to their psychological problems sometimes preventing them from completing the questionnaires. Substantial loss to follow-up is a common problem in psychological health research;12,53,54 however, in this study the rate of loss to follow-up was similar in both groups, which allowed the authors to account for it using multiple imputation and linear mixed models (likelihood approach).

GPs and participants could not be blinded. This may have caused performance bias; that is, participants and care providers in the intervention group could have been more motivated to complete the questionnaires, and adhere to the recommendations. Additionally, GPs could have applied skills they learned from PsyScan to their patients who were in the control group. The authors feel, however, that this learning bias would be small for a variety of reasons. First, PsyScan consists of technical elements (for example, the automated generation of scores and diagnostic and therapeutic advice) that would have been difficult to replicate without the software. In addition, the mean number of patients in the intervention group per GP was no more than four; considering this, and the extent of the diversity in psychological problems in general practice, it is likely that there was little opportunity for GPs to discern patterns to learn that they could then apply to patients in the control group.

As the severity of psychological problems

<table>
<thead>
<tr>
<th>Table 4. PsyScan results for intervention group (n = 176)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Possible scores*</td>
</tr>
<tr>
<td>Participants completed PsyScan, n (%)</td>
</tr>
<tr>
<td>Mean distress screener score (SD)</td>
</tr>
<tr>
<td>Participants with positive distress screener score (&gt;3), n (%)</td>
</tr>
<tr>
<td>Mean 4DSQ stress score (SD)</td>
</tr>
<tr>
<td>Mean 4DSQ depression score (SD)</td>
</tr>
<tr>
<td>Mean 4DSQ anxiety score (SD)</td>
</tr>
<tr>
<td>Mean 4DSQ somatisation score (SD)</td>
</tr>
<tr>
<td>Participants had ICPC coding in accordance with PsyScan advice, n (%)</td>
</tr>
<tr>
<td>Participants had medication in accordance with PsyScan advice, n (%)</td>
</tr>
<tr>
<td>Participants had treatment/referral in accordance with PsyScan advice, n (%)</td>
</tr>
</tbody>
</table>

*Higher scores indicate higher symptom levels. 4DSQ = Four-Dimensional Symptom Questionnaire. ICPC = International Classification of Primary Care. SD = standard deviation.

| Table 5. Generated costs: results from linear regression analyses, adjusting for age, sex, socioeconomic status, prior psychological symptoms and baseline SCL-90-R score (n = 174) |
|-----------------------------------------------|-----------------------------------------------|
| Intervention group, n = 95                    | Control group, n = 79                         |
| Mean 1-year cost per participant, € (SD)      | Mean 1-year cost per participant, € (SD)      |
| Healthcare consumption                        | 2277 [2449]                                   |
| Use of medication                             | 176 [1016]                                    |
| Paid work absenteeism, short term (<4 weeks)  | 3225 [7416]                                   |
| Paid work absenteeism, long term (>4 weeks)   | 3832 [8035]                                   |
| Productivity loss, paid work                  | 3301 [8458]                                   |
| Productivity loss, unpaid work                | 13,622 [16,398]                               |
| Totala                                        | 12,487 [14,862]                               |

*Total values are different because of rounding. β = standardised regression coefficient. SCL-90-R = Symptom Checklist-90-Revised. SD = standard deviation.
at baseline was relatively low, it might have been more difficult to achieve a successful treatment result (it is more difficult to reduce low scores by ≥50%). As such, the assumption that 80% of the intervention group and 70% of control group participants would achieve a successful treatment result was, perhaps, too optimistic; however, a statistically significant result was still obtained.

PsyScan was associated with more clinically relevant and statistically significant patient recovery without being associated with statistically significantly higher costs. However, a substantial part of the cost data was missing, so care must be taken when interpreting the cost-effectiveness results.

Comparison with existing literature
In the intervention group, patient recovery was ongoing throughout follow-up, whereas, in the group receiving usual care, it appeared to weaken. Hypothetically, PsyScan provided information and guidance to GPs, allowing the offer of care with longer-lasting effects. The positive effects of PsyScan were due to patients being managed more appropriately. The benefit of PsyScan was also illustrated by feedback from several GPs and participants, who stated that it resulted in a better understanding between patient and doctor; this is supported by literature showing that good patient–doctor communication improves outcomes.55 Similarly, PsyScan may have helped GPs and participants to assess a broader range of symptoms, whereas usual care might focus on some prominent problems; for example, somatic problems are known to distract from the psychological problems that cause them.35 Furthermore, many individuals have trouble expressing psychological problems to GPs; as web-based assessments require less social interaction, people may divulge more personal information than they do in face-to-face consultations.36–40

Dutch guidelines urge GPs to be reticent when prescribing psychiatric medication and encourage them to make greater use of non-pharmaceutical alternatives, especially in the case of moderate problems.32–36 This may have resulted in relatively low prescription rates compared with other settings.41 Anxiolytics, hypnotics, and sedatives formed no part of the PsyScan advice and, accordingly, were prescribed substantially less often for intervention participants than for control group participants in this study.

Implications for research and practice
From literature and preliminary studies carried out in general practice, it is known that primary care providers and patients perceive a need for pragmatic, comprehensive, and integrated tools to use in psychological care.32 Not all GPs welcome tools (electronic or otherwise); some may prefer to rely on experience and clinical judgement, which are undoubtedly among the most powerful tools they can use.53 Nevertheless, this study has shown that PsyScan can be a beneficial supplement to create more uniformity, it can provide more useful information with less effort, and it includes elements for every GP. Some GPs will only want to use the digital administration of the 4DSQ, diagnostic and therapeutic advice, or a cause inventory; moreover, different elements are of different value for different patients. However, PsyScan has demonstrated that it can be highly effective in structuring individualised care to patients in general practice.

This study has demonstrated PsyScan’s clinical effects and associated costs. Future research should be undertaken to show how it can be implemented in different settings and to further assess its effects and the cost-effectiveness of using this e-tool.

Funding
The development of PsyScan was funded by the Department of Family Medicine of Maastricht University and Stichting Gezondheidscentra Eindhoven (SGE). This trial was funded by SGE through two healthcare insurance companies, Centraal Ziekenfonds and Stichting Volksgezondheidszorg.

Ethical approval
This trial was approved by the Medical Ethical Committee of Maastricht University Medical Center (reference: NL44597.068.13/13-3-034) and registered in the ClinicalTrials.gov database (NCT01971307).

Provenance
Freely submitted; externally peer reviewed.

Competing interests
All the authors have contributed to the development of PsyScan but none has economic interests in PsyScan.

Discuss this article
Contribute and read comments about this article: bjgp.org/letters


